|
|
|
Volumn 6, Issue 2, 2008, Pages 98-100
|
|
Advances in HER2-positive breast cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
BEVACIZUMAB;
CAPECITABINE;
CARBOPLATIN;
DOCETAXEL;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ESTROGEN RECEPTOR;
LAPATINIB;
MEMBRANE PROTEIN;
PERTUZUMAB;
SOMATOMEDIN C RECEPTOR;
TAXANE DERIVATIVE;
TRASTUZUMAB;
TYROSINE KINASE RECEPTOR;
VASCULOTROPIN;
ARTICLE;
BREAST CANCER;
CANCER INHIBITION;
CANCER RECURRENCE;
CARDIOTOXICITY;
CLINICAL TRIAL;
CONGESTIVE CARDIOMYOPATHY;
CONGESTIVE HEART FAILURE;
DRUG PROTEIN BINDING;
DRUG RECEPTOR BINDING;
DRUG RESEARCH;
DRUG TARGETING;
FLUORESCENCE IN SITU HYBRIDIZATION;
FOOD AND DRUG ADMINISTRATION;
HIGH RISK PATIENT;
HISTOPATHOLOGY;
HUMAN;
MONOTHERAPY;
PROTEIN SYNTHESIS INHIBITION;
RISK REDUCTION;
UNITED STATES;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
RECEPTOR, ERBB-2;
|
|
EID: 41649087777
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (5)
|
